R&D investment by the one thousand public companies that spend the most on R&D increased 9.6% in 2011 to $603 billion after a 9.3% increase the previous year, according to Booz & Company’s eighth annual “Global Innovation 1000” report. R&D spending by the computing and electronics, health care and automobile industries accounted for 28%, 21% […]
The results of the first phase of the 1000 Genomes Project have been published in Nature. The $120 million project sequenced the genomes of 1,092 people from 14 populations to study variants in the human genome that are present in at least one in 50 individuals. When the project is complete next year, it will […]
Since 2009, six prominent US sterile-injectable drug makers have received FDA warnings regarding manufacturing procedures. As a result, the manufacturing capacity for injectables has been reduced by almost one-third, according to a congressional report. Four of the firms shut down or decreased production to address the issues. Compounding pharmacies have attempted to provide the products, […]
According to the results of IBO’s Fall 2012 Business Climate Survey, expectations for near-term instrument and laboratory product sales have hit their lowest point since spring 2009 (see graph, page 6). Twenty-four percent of respondents expect instrument and lab product sales to decline industry wide over the calendar-year fourth quarter 2012 and first quarter 2013. […]
Development of a new type of preventive cancer vaccine is generating funding for biotechnology firms and hope for new therapies. The first such vaccine to come to market was Dendreon’s Provenge, which won FDA approval in 2010 for the treatment of metastatic prostate cancer and is customized for each patient. The new approach seeks to […]
A report released this month by the Department of Health and Human Services’ (DHHS) Office of Inspector General indicates that many of the 127 immune support and weight loss supplements it analyzed did not adhere to FDA guidance. The Inspector General found that 20% of the supplements’ labels included illegal claims to prevent, diagnose or […]
Earlier this month, the European Commission (EC) released the “Communication on the Second Regulatory Review on Nanomaterials” report (the Review), along with a Working Paper on nanomaterial types and uses (the Working Paper). The Review highlighted the potential benefits of new nanomaterials and new uses, including electronics, solar panels, batteries and biomedical applications. Established uses […]
A July survey of 156 chemical industry senior executives found that 63% plan to increase capital spending next year, with 81% of Asian executives expecting to do so. In 2012, 38% of executives expect to invest between 3% to 5% of revenues in R&D, while 31% expect to invest between 2% and 3%. Eighty percent […]
Stem cell research is steadily moving forward. As the award this month of the Nobel Prize in Medicine to Dr. Shinya Yamanaka, who created the first induced pluripotent stem cells (iPSCs), shows, the ability to create stem cells from somatic cells has changed scientific research. Contributing to the research’s advancement has been rapid progress in […]
R&D investment by the one thousand public companies that spend the most on R&D increased 9.6% in 2011 to $603 billion after a 9.3% increase the previous year, according to Booz & Company’s eighth annual “Global Innovation 1000” report. R&D spending by the computing and electronics, health care and automobile industries accounted for 28%, 21% […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
